Literature DB >> 16681811

Stress as a cause of chronic recurrent vulvovaginal candidosis and the effectiveness of the conventional antimycotic therapy.

Harald Meyer1, Sigurd Goettlicher, Werner Mendling.   

Abstract

Chronic Candida vulvovaginitis cannot, at present, be treated effectively with local or oral antimycotic medication. Göttlicher & Meyer [Vulvovaginalmykose. Klinische Ergebnisse einer epidemiologischen Langzeitstudie, Thieme, Stuttgart (1998); Mycoses41 (1998) 49] formulated a hypothesis to explain this fact. They say that stress is the main cause of vulvovaginal mycosis, and that frequently cited predisposing somatic risk factors are not causing the illness. Two research projects were carried out to test this hypothesis. The first project was conceived to provide direct evidence for two empirical statements derived from the Göttlicher-Meyer hypothesis: (i) stress as a predictor of vulvovaginitis is least valid as the commonly assumed somatic factors and (ii) combinations of factors that reliably discriminate index women from symptom-free women point to aspects of psychosocial development, particularly stress, and not to somatic factors. Between March and November 1999, 309 successive patients were randomly chosen from those successively treated in one in-patient and two out-patient settings. Of those chosen, 117 had had at least one episode of vaginal candidosis within the 2 years prior to enlistment in the study. The remaining 192 patients had experienced no such illness. For the 117 index patients both of the above empirical statements were confirmed by statistical analyses. The second project was designed to test predictions concerning the ineffectiveness of traditional antimycotic treatment derived from the Göttlicher-Meyer hypothesis. Three different empirical statements were derived from the hypothesis--each based on the assumption of a Poisson distribution of relapses that remains uninfluenced by treatment attempts. Each of the statements was tested and confirmed in independent samples--the first in the sample used in project one, the second in a sample of 206 women insured by public Healths Management Organizations (HMOs) and the third in a sample of 179 women insured by private HMOs. Each patient had evidenced Candida albicans vulvovaginitis at least once in the time interval between 1996 and 2000. Statistical analyses confirmed each of the empirical statements, thereby substantiating the Göttlicher-Meyer hypothesis. The authors conclude that (i) psychosocial factors, particularly stress, are the primary causes of Candida albicans vulvovaginitis. Accompanying somatic factors are of little statistical significance in explaining occurrence and relapse. (ii) Traditional antimycotic treatment influences only the symptoms of the illness, not its causes, and has no effect on the probability of a relapse. Increased treatment effectiveness can be achieved only at the cost of a complete re-orientation concerning the causes of vaginal mycosis. Interventions designed to strengthen the patients' immune response are among the most promising.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16681811     DOI: 10.1111/j.1439-0507.2006.01235.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  14 in total

1.  Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).

Authors:  W Mendling; K Friese; I Mylonas; E-R Weissenbacher; J Brasch; M Schaller; P Mayser; I Effendy; G Ginter-Hanselmayer; H Hof; O Cornely; M Ruhnke
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

2.  Vulvovaginal Candidosis (Excluding Mucocutaneous Candidosis): Guideline of the German (DGGG), Austrian (OEGGG) and Swiss (SGGG) Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry Number 015/072, September 2020).

Authors:  Alex Farr; Isaak Effendy; Brigitte Frey Tirri; Herbert Hof; Peter Mayser; Ljubomir Petricevic; Markus Ruhnke; Martin Schaller; Axel P A Schäfer; Birgit Willinger; Werner Mendling
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-04-14       Impact factor: 2.915

3.  Effects of psychological stress and fluoxetine on development of oral candidiasis in rats.

Authors:  María J Núñez; Silvia Novío; Juan Antonio Suárez; José Balboa; Manuel Freire-Garabal
Journal:  Clin Vaccine Immunol       Date:  2010-02-03

4.  Role of phosphatidylinositol-3-kinase (PI3K), extracellular signal-regulated kinase (ERK) and nuclear transcription factor kappa beta (NF-k beta) on neutrophil phagocytic process of Candida albicans.

Authors:  E Giraldo; L Martin-Cordero; M D Hinchado; J J Garcia; E Ortega
Journal:  Mol Cell Biochem       Date:  2009-07-16       Impact factor: 3.396

Review 5.  Local treatment of vulvovaginal candidosis : general and practical considerations.

Authors:  José das Neves; Eugénia Pinto; Branca Teixeira; Gustavo Dias; Patrocínia Rocha; Teresa Cunha; Bárbara Santos; Maria H Amaral; Maria F Bahia
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives.

Authors:  Christophe d'Enfert; Ann-Kristin Kaune; Leovigildo-Rey Alaban; Sayoni Chakraborty; Nathaniel Cole; Margot Delavy; Daria Kosmala; Benoît Marsaux; Ricardo Fróis-Martins; Moran Morelli; Diletta Rosati; Marisa Valentine; Zixuan Xie; Yoan Emritloll; Peter A Warn; Frédéric Bequet; Marie-Elisabeth Bougnoux; Stephanie Bornes; Mark S Gresnigt; Bernhard Hube; Ilse D Jacobsen; Mélanie Legrand; Salomé Leibundgut-Landmann; Chaysavanh Manichanh; Carol A Munro; Mihai G Netea; Karla Queiroz; Karine Roget; Vincent Thomas; Claudia Thoral; Pieter Van den Abbeele; Alan W Walker; Alistair J P Brown
Journal:  FEMS Microbiol Rev       Date:  2021-05-05       Impact factor: 16.408

7.  Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA.

Authors:  Samuel Aballéa; Florent Guelfucci; Julian Wagner; Amine Khemiri; Jean-Paul Dietz; Jack Sobel; Mondher Toumi
Journal:  Health Qual Life Outcomes       Date:  2013-10-11       Impact factor: 3.186

8.  Highlights Regarding Host Predisposing Factors to Recurrent Vulvovaginal Candidiasis: Chronic Stress and Reduced Antioxidant Capacity.

Authors:  Luciene Akimoto-Gunther; Patrícia de Souza Bonfim-Mendonça; Gisele Takahachi; Mary Mayumi T Irie; Sônia Miyamoto; Márcia Edilaine Lopes Consolaro; Terezinha I Estivalet Svidzinsk
Journal:  PLoS One       Date:  2016-07-14       Impact factor: 3.240

9.  Lamisil versus clotrimazole in the treatment of vulvovaginal candidiasis.

Authors:  Ali Zarei Mahmoudabadi; Mahin Najafyan; Eskandar Moghimipour; Maryam Alwanian; Zahra Seifi
Journal:  Iran J Microbiol       Date:  2013-03

10.  Vulvovaginal Self-care Under the Shadow of the Covid-19 Pandemic.

Authors:  Farzaneh Rashidi Fakari; Fahimeh Rashidi Fakari; Zahra Kiani; Masumeh Ghazanfarpour
Journal:  Arch Sex Behav       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.